Upon joining the study, the patient will begin the initial treatment phase. This involves receiving medications through an intravenous (IV) infusion.

The medications administered are datopotamab deruxtecan and pembrolizumab. Both are given as a solution for infusion.

The frequency and dosage of these medications will be determined by the study protocol and the patient’s specific condition.

Throughout the treatment period, the patient’s health and response to the medication will be closely monitored.

Regular visits will be scheduled to assess the patient’s condition, including laboratory tests and imaging studies to evaluate the progression of the disease.

The patient’s overall health, including heart function and any side effects, will be evaluated to ensure safety and effectiveness of the treatment.

The primary goal of the study is to measure progression-free survival (PFS), which is the time from the start of treatment until the disease progresses or the patient passes away from any cause.

This assessment will be conducted by an independent review to ensure unbiased results.

Another key objective is to evaluate overall survival (OS), which is the duration from the start of treatment until death from any cause.

This measure helps determine the long-term effectiveness of the treatment.

The treatment phase will continue until the study’s end date or until the patient experiences significant disease progression or adverse effects that necessitate discontinuation.

The estimated end date for the trial is April 30, 2028.